AN2 Therapeutics, University of Georgia Research Foundation to develop therapy for Chagas disease
Chagas disease is caused by the parasite Trypanosoma cruzi, which is primarily transmitted through a subspecies of blood-feeding…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Oct 23
Chagas disease is caused by the parasite Trypanosoma cruzi, which is primarily transmitted through a subspecies of blood-feeding…
19 Oct 23
Grant will fund Investigational New Drug enabling studies and manufacturing for CSX-1004 SQ
19 Oct 23
The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink technology for development of additional…
18 Oct 23
The partnership will initially focus on Assembly Bio’s next-gen core inhibitor ABI-4334, intended for HBV, long-acting helicase-primase inhibitor…
18 Oct 23
The partnership will combine Monte Rosa’s highly differentiated QuEEN discovery engine with Roche’s expertise in providing transformative therapies…
18 Oct 23
Takeda said the safety profile of Alofisel remained in line with previous research, with no new safety concerns…
18 Oct 23
Co-led by Eclipse and GE HealthCare, the investment will accelerate research, streamline supply chains, and make targeted radiopharmaceutical…
18 Oct 23
WuXiUI ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients’ needs in…
17 Oct 23
In the US, Keytruda has been approved in combination with platinum-based chemotherapy as neoadjuvant treatment for resectable NSCLC…
17 Oct 23
The deal, builds on the previously announced deal and licence agreement in 2022, is intended to combine LCB’s…